RNS Number : 8127K
Integrated Diagnostics Holdings PLC
24 April 2020

Integrated Diagnostics Holdings Plc Notice of results


24 April 2020


(London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), IDHC on the London Stock Exchange, a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, will publish its results for the year ended 31 December 2019 on Tuesday 28 April 2020 at 7am GMT.

Due to the ongoing concerns regarding the COVID-19 pandemic and in the interest of participants' safety, management will not be hosting an investor presentation and will instead hold a conference call on Tuesday 28 April 2020 at 2pm BST | 4pm EEST.

A live audio webcast can be accessed at this link and you may dial in using the conference call details below:

•     Access code: 1181767#

•     UK dial in: +44 20 7107 9450

•     USA dial in: +1 (866) 499-2813

Please email ebba.hellsten@panmure.com if you would like to attend the presentation.




+20 (0)2 3345 5530

Sherif El-Ghamrawi,

Investor Relations Director

+20 (0)10 0447 8699




About Integrated Diagnostics Holdings

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Scan (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 1,400 diagnostics tests. From its base of 424 branches as of 30 June 2019, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern and African markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015.


IDH's forward-looking strategy rests on leveraging its established business model to achieve four key strategic goals, namely: (1) continue to expand customer reach; (2) increase the number of tests per patient; (3) expand into new geographic markets through selective, value-accretive acquisitions; and (4) introduce new medical services by leveraging the Group's network and reputable brand position. Learn more at idhcorp.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.